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Abstract
BACKGROUND—There is no evidence from randomized trials to support a strategy of lowering
systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We
investigated whether therapy targeting normal systolic pressure (i.e., <120 mm Hg) reduces major
cardiovascular events in participants with type 2 diabetes at high risk for cardiovascular events.
METHODS—A total of 4733 participants with type 2 diabetes were randomly assigned to
intensive therapy, targeting a systolic pressure of less than 120 mm Hg, or standard therapy,
targeting a systolic pressure of less than 140 mm Hg. The primary composite outcome was
nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The mean
follow-up was 4.7 years.
RESULTS—After 1 year, the mean systolic blood pressure was 119.3 mm Hg in the intensive-
therapy group and 133.5 mm Hg in the standard-therapy group. The annual rate of the primary
outcome was 1.87% in the intensive-therapy group and 2.09% in the standard-therapy group
(hazard ratio with intensive therapy, 0.88; 95% confidence interval [CI], 0.73 to 1.06; P = 0.20).
The annual rates of death from any cause were 1.28% and 1.19% in the two groups, respectively
(hazard ratio, 1.07; 95% CI, 0.85 to 1.35; P = 0.55). The annual rates of stroke, a prespecified
secondary outcome, were 0.32% and 0.53% in the two groups, respectively (hazard ratio, 0.59;
95% CI, 0.39 to 0.89; P = 0.01). Serious adverse events attributed to antihypertensive treatment
occurred in 77 of the 2362 participants in the intensive-therapy group (3.3%) and 30 of the 2371
participants in the standard-therapy group (1.3%) (P <0.001).
CONCLUSIONS—In patients with type 2 diabetes at high risk for cardiovascular events,
targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm
Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular
events. (ClinicalTrials.gov number, NCT00000620.)
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Diabetes mellitus increases the risk of cardiovascular disease by a factor of two to three at
every level of systolic blood pressure.1 Because cardiovascular risk in patients with diabetes
is graded and continuous across the entire range of levels of systolic blood pressure, even at
prehypertensive levels, the Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommended
beginning drug treatment in patients with diabetes who have systolic blood pressures of 130
mm Hg or higher, with a treatment goal of reducing systolic blood pressure to below 130
mm Hg.1–3 There is, however, a paucity of evidence from randomized clinical trials to
support these recommendtions. The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) blood pressure trial (ACCORD BP)4 tested the effect of a target systolic blood
pressure below 120 mm Hg on major cardiovascular events among high-risk persons with
type 2 diabetes. We present here the main results of the ACCORD BP trial.
METHODS
STUDY DESIGN
ACCORD was a randomized trial conducted at 77 clinical sites organized into seven
networks in the United States and Canada (for a full list of participating institutions and
investigators, see Section 1 in Supplementary Appendix 1, available with the full text of this
article at NEJM.org). The trial enrolled 10,251 high-risk participants with type 2 diabetes
mellitus.5 All participants were randomly assigned to either intensive or standard glycemic
control (the ACCORD glycemia trial). In addition, 5518 of the ACCORD participants were
also randomly assigned (in a 2-by-2 factorial design) to either simvastatin plus fenofibrate or
simvastatin plus placebo (the ACCORD lipid trial), and the remaining 4733 participants
were also randomly assigned (in a 2-by-2 factorial design) to either intensive or standard
blood-pressure control (the ACCORD blood-pressure trial). Details of the randomization are
provided in Section 3 of Supplementary Appendix 1. The trial was sponsored by the
National Heart, Lung, and Blood Institute (NHLBI). The protocol was approved by the
institutional review board or ethics committee at each center and by an independent protocol
review committee appointed by the NHLBI. The main results of the ACCORD glycemia
trial have been published previously,6 and the main results of the ACCORD Lipid trial are
published elsewhere in this issue of the Journal.7 The ACCORD trial protocol and
amendments are available in Supplementary Appendix 2.
ELIGIBILITY CRITERIA AND RECRUITMENT
Inclusion criteria for the glycemia trial are described in detail elsewhere.5 In brief,
participants were eligible if they had type 2 diabetes mellitus and a glycated hemoglobin
level of 7.5% or more and were 40 years of age or older with cardiovascular disease or 55
years of age or older with anatomical evidence of a substantial amount of atherosclerosis,
albuminuria, left ventricular hypertrophy, or at least two additional risk factors for
cardiovascular disease (dyslipidemia, hypertension, smoking, or obesity). Exclusion criteria
included a body-mass index (the weight in kilograms divided by the square of the height in
meters) of more than 45, a serum creatinine level of more than 1.5 mg per deciliter (132.6
µmol per liter), and other serious illness. Participants with a systolic blood pressure between
130 and 180 mm Hg who were taking three or fewer antihypertensive medications and who
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had the equivalent of a 24 -hour protein excretion rate of less than 1.0 g were also eligible
for the blood-pressure trial (see Section 4 in Supplementary Appendix 1).8 All participants
provided written informed consent.
Recruitment occurred during two noncontiguous periods: 491 participants in the blood-
pressure trial were recruited from January 2001 through early June 2001 during a
“vanguard” phase, and the remaining 4242 participants were recruited from January 2003
through October 2005 during the main trial phase. An upper age limit of 79 years was added
to the eligibility criteria for the main trial recruitment.
TRIAL PROCEDURES
The ACCORD BP trial was a nonblinded trial in which participants were randomly assigned
to intensive therapy that targeted systolic blood pressures of less than 120 mm Hg or
standard therapy that targeted systolic blood pressures of less than 140 mm Hg. Treatment
strategies that are currently available in clinical practice were used to lower blood pressure.
Randomization was performed centrally on the study’s Web site with the use of permuted
blocks to maintain concealment of future study-group assignments.
The approach to the management of blood pressure has been described elsewhere.4 The
schedules of visits for the assessment and management of blood pressure differed according
to treatment group. For participants in the intensive-therapy group, visits to assess blood
pressure were scheduled once a month for 4 months and every 2 months thereafter; for
participants in the standard-therapy group, visits were scheduled at months 1 and 4 and
every 4 months thereafter. Additional visits were scheduled as needed in both groups to
monitor and ensure appropriate implementation of the study intervention strategies. In both
blood-pressure groups, participants who were assigned to intensive glycemic therapy had
more frequent contacts for the management of glycemia, but blood pressure was not
monitored at these additional visits.
The ACCORD BP trial was a study of a treatment strategy to achieve specific systolic
blood-pressure goals, rather than an evaluation of any specific drug regimen. However, all
the antihypertensive regimens were to include drug classes that had been shown to result in a
reduction in cardiovascular events among participants with diabetes. Details of the
assessment of blood pressure, the adjustment of medication doses, and antihypertensive drug
regimens are provided in Sections 8 and 9 in Supplementary Appendix 1. Antihypertensive
drugs were donated by Abbott Laboratories, AstraZeneca Pharmaceuticals, Glaxo-
SmithKline Pharmaceuticals, King Pharmaceuticals, Sanofi-Aventis U.S., and Novartis
Pharmaceuticals. Sphygmomanometers were donated by Omron Healthcare. The companies
that donated the drugs and devices had no role in the design of the study, the accrual or
analysis of the data, or the preparation of the manuscript.
At the 4-month visits that both treatment groups were scheduled to attend, information on
study outcomes and adverse events was ascertained, blood samples were obtained, and
clinical examinations were performed. The occurrence of self-reported symptoms of
swelling or of dizziness on standing during the previous month was assessed as part of a
standardized symptom checklist that was administered at baseline and at 1, 3, and 4 years
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after randomization to a random sample of 969 participants who were assessed for health-
related quality of life.
TRIAL OUTCOMES
The primary outcome for all three ACCORD trials was the first occurrence of a major
cardiovascular event, which was defined as the composite of nonfatal myocardial infarction,
nonfatal stroke, or cardiovascular death. Prespecified secondary outcomes included the
combination of the primary outcome plus revascularization or hospitalization for congestive
heart failure (termed the “expanded macrovascular outcome”); the combination of a fatal
coronary event, nonfatal myocardial infarction, or unstable angina (termed “major coronary
disease events”); nonfatal myocardial infarction; fatal or nonfatal stroke; nonfatal stroke;
death from any cause; death from cardiovascular causes; and hospitalization or death due to
heart failure. Definitions of each prespecified end point and information regarding methods
of ascertainment are included in Section 6 in Supplementary Appendix 1.
Since all the antihypertensive medications used in the trial were approved by the Food and
Drug Administration and were used according to approved labeling, we limited detailed data
collection on serious adverse events to those attributed by investigators to antihypertensive
medications (see Section 7 in Supplementary Appendix 1). Clinical and laboratory variables,
including serum potassium and creatinine levels and estimated glomerular filtration rate,9
were also examined as potential adverse effects.
STATISTICAL ANALYSIS
With a planned sample size of 4200 participants, the ACCORD BP trial was designed to
have 94% power to detect a 20% reduction in the rate of the primary outcome for
participants in the intensive-therapy group, as compared with those in the standard-therapy
group, assuming a two-sided alpha level of 0.05, a primary-outcome rate of 4% per year in
the standard-therapy group, and a planned average follow-up of 5.6 years for participants
who did not have an event. Since ACCORD was a factorially designed trial, the targeted
number of participants and the determination of sample size were made under the
assumption that the intensive glucose-lowering intervention would produce a 15% benefit.5
Statistical analyses were conducted at the coordinating center with the use of S-Plus
software, version 8.0 (Insightful) or SAS software, version 9.1 (SAS Institute). Baseline
characteristics and key safety outcomes were compared between the two study groups with
the use of the chi-square test, Fisher’s exact test, Wilcoxon rank-sum test, and the two-
sample t-test.
Analyses of primary and secondary outcomes were performed with the use of time-to-event
methods according to the intention-to-treat principle. Event rates are expressed as the
percentage of events per follow-up year, taking into account the censoring of follow-up data.
Kaplan-Meier estimates were used to calculate the proportion of participants who had an
event during follow-up.
Occurrences of primary and secondary outcomes in the two study groups were compared
with the use of hazard ratios and 95% confidence intervals. Two-sided P values were
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calculated with the use of likelihood-ratio tests from Cox proportional-hazards regression
analyses. The Cox models contained a term representing study-group assignments plus
terms accounting for the following prespecified stratifying variables: assignment to the
intensive glucose-lowering intervention, each of the seven clinical-center networks, and the
presence or absence of a previous cardiovascular event. Using the log of follow-up time as a
time-dependent covariate, we found no evidence of important departures from the
assumption of proportionality.10 We examined the consistency of the intervention effect on
the primary outcome among nine prespecified subgroups using statistical tests of interaction
between the treatment effect and the subgroup within the Cox models.
During the trial, an independent data and safety monitoring committee appointed by the
NHLBI monitored the primary outcome (11 times) and total rate of death (7 times) with the
use of O’Brien–Fleming boundaries determined by the Lan–DeMets approach. For these
two outcomes, P values were adjusted to account for the number, timing, and results of
interim analyses. All other P values for secondary outcomes and for subgroup analyses are
nominal and have not been adjusted for multiple comparisons.
All analyses are based on observed data with the assumption that missing data were missing
completely at random. For the longitudinal analysis of systolic blood pressure, a sensitivity
analysis with the use of maximum-likelihood methods, under the assumption that the




A total of 4733 participants were enrolled in the ACCORD BP trial. Of these, 2362 were
randomly assigned to intensive blood-pressure control and 2371 were assigned to standard
therapy. Baseline characteristics were generally similar between the two groups (Table 1).
The mean age of the participants was 62.2 years; 47.7% were women and 33.7% had
cardiovascular disease at baseline. The mean systolic and diastolic blood pressures of the
participants at baseline were 139.2 mm Hg and 76.0 mm Hg, respectively.
At the end of the trial (June 2009), vital status was known for 95.1% of the randomly
assigned participants. The mean duration of follow-up for the rate of death was 5.0 years, or
98.4% of the potential person-years of follow-up that would have been available if all
surviving participants had been followed until the end of the trial. The mean duration of
follow-up for the primary outcome was 4.7 years (94.8% of the potential follow-up). At the
final follow-up visit, the rate of current smoking was 8.5% in the intensive-therapy group
and 7.5% in the standard-therapy group (P = 0.44).
BLOOD PRESSURE
The two therapeutic strategies quickly resulted in different systolic blood-pressure levels
(Fig. 1). After the first year of therapy, the average systolic blood pressure at the 4-month
protocol visits that both groups attended was 119.3 mm Hg (95% confidence interval [CI],
118.9 to 119.7) in the intensive-therapy group and 133.5 mm Hg (95% CI, 133.1 to 133.8) in
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the standard-therapy group, resulting in an average between-group difference of 14.2 mm
Hg (95% CI, 13.7 to 14.7). The corresponding mean diastolic blood pressures were 64.4
(95% CI, 64.1 to 64.7) and 70.5 (95% CI, 70.2 to 70.8), for an average difference of 6.1 mm
Hg (95% CI, 5.7 to 6.5) (Section 14 in Supplementary Appendix 1).
The lower blood pressure in the intensive-therapy group was associated with a greater
exposure to drugs from every class (Fig. 1, and Section 11 in Supplementary Appendix 1).
The mean number of medications after the first year was 3.4 (95% CI, 3.4 to 3.5) in the
intensive-therapy group and 2.1 (95% CI, 2.1 to 2.2) in the standard-therapy group.
ADVERSE EVENTS
As compared with the standard-therapy group, the intensive-therapy group had significantly
higher rates of serious adverse events attributed to antihypertensive treatment, as well as
higher rates of hypokalemia and elevations in serum creatinine level (Table 2). The mean
estimated glomerular filtration rates were significantly lower in the intensive-therapy group
than in the standard-therapy group at the last visit. There were significantly more instances
of an estimated glomerular filtration rate less than 30 ml per minute per 1.73 m2 of body-
surface area in the intensive-therapy group than in the standard-therapy group (99 vs. 52
events, P<0.001), although only 38 participants in the intensive-therapy group and 32 in the
standard-therapy group had two or more instances of that rate (P = 0.46). The frequency of
macroalbuminuria at the final visit was significantly lower in the intensive-therapy group
than in the standard-therapy group, and there was no between-group difference in the
frequency of end-stage renal disease or the need for dialysis. In the random sample of 969
participants who were assessed for health-related quality of life, the frequency of symptoms
of orthostatic hypotension was similar between the groups.
CLINICAL OUTCOMES
The primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, or death
from cardiovascular causes occurred in 445 participants. The rate was 1.87% per year in the
intensive-therapy group as compared with 2.09% per year in the standard-therapy group,
with no significant between-group difference (hazard ratio with intensive therapy, 0.88; 95%
CI, 0.73 to 1.06; P = 0.20) (Table 3 and Fig. 2).
There were 294 deaths from any cause and 118 deaths from cardiovascular causes (Table 3).
Rates of death from any cause were 1.28% per year in the intensive-therapy group and
1.19% in the standard-therapy group (hazard ratio with intensive therapy, 1.07; 95% CI,
0.85 to 1.35; P = 0.55). Rates of death from cardiovascular causes were 0.52% per year in
the intensive-therapy group and 0.49% in the standard-therapy group (hazard ratio, 1.06;
95% CI, 0.74 to 1.52; P = 0.74).
The two study groups did not differ significantly with respect to most of the other secondary
outcomes. Nominally significant differences were seen in the rate of total stroke (0.32% per
year in the intensive-therapy group vs. 0.53% per year in the standard-therapy group; hazard
ratio, 0.59; 95% CI, 0.39 to 0.89; P = 0.01) and in the rate of nonfatal stroke (0.30% per year
in the intensive-therapy group vs. 0.47% per year in the standard-therapy group; hazard
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ratio, 0.63; 95% CI, 0.41 to 0.96; P = 0.03). There were no significant interactions among
prespecified subgroups (see Section 17 in Supplementary Appendix 1).
DISCUSSION
Intensive antihypertensive therapy in the ACCORD BP trial did not significantly reduce the
primary cardiovascular outcome or the rate of death from any cause, despite the fact that
there was a significant and sustained difference between the intensive-therapy group and the
standard-therapy group in mean systolic blood pressure. There was also no significant
benefit with respect to most of the secondary trial outcomes. At a significance level of less
than 0.05, intensive blood-pressure management did reduce the rate of two closely
correlated secondary outcomes — total stroke and nonfatal stroke. Assuming that this
finding was real, the number needed to undergo intensive blood-pressure management to
prevent one stroke over the course of 5 years was 89. These effects would be consistent with
the findings of two meta-analyses of the effect of a reduction of 10 mm Hg in systolic blood
pressure on the incidence of stroke11,12; the meta-analyses showed a relative risk with
blood-pressure reduction of 0.64 with the use of data from observational studies and of 0.59
with the use of data from drug-treatment trials.12
The interpretation of the ACCORD BP results is complicated by the fact that the event rate
observed in the standard-therapy group was almost 50% lower than the expected rate. This
result may have been a consequence of the frequent use of statins and of inclusion criteria
that directed participants with dyslipidemia into the ACCORD lipid trial, leaving
participants who were at lower risk in the blood-pressure trial.5 The reduced power was
reflected in the relatively wide confidence interval that does not exclude a 27% benefit for
the primary end point.
There were some signals of possible harm associated with intensive blood-pressure control,
including a rate of serious adverse events that was significantly higher in the intensive-
therapy group than in the standard-therapy group. Both the estimated glomerular filtration
rate and macroalbuminuria were reduced, but the implications of these changes on
cardiovascular and renal outcomes are uncertain.
The United Kingdom Prospective Diabetes Study13,14 and a post hoc subgroup analysis of
the Hypertension Optimal Treatment (HOT) trial15’16 showed reductions in cardiovascular
events with antihypertensive therapy among patients with type 2 diabetes mellitus, but the
participants in their intensively treated groups had much higher mean systolic blood-
pressure levels (144 mm Hg in both cases) than did the participants in either group of our
trial. In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation trial (ADVANCE; ClinicalTrials.gov number,
NCT00145925),17 active treatment with an angiotensin-converting–enzyme inhibitor and a
thiazide-type diuretic reduced the rate of death but did not significantly reduce a composite
macrovascular outcome. However, the ADVANCE trial had no specified blood-pressure
goals, and the mean systolic blood pressure in the intensive group (135 mm Hg) was not as
low as the mean systolic blood pressure even in the ACCORD standard-therapy group. It is
possible that lowering systolic blood pressure from the mid-130s to approximately 120 mm
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Hg does not further reduce most cardiovascular events or the rate of death, and most of the
benefit from lowering blood pressure is achieved by targeting a goal of less than 140 mm
Hg. Alternatively, it is possible that 5 years is not long enough to see significant cardiac
benefits from the normalization of systolic blood pressure among persons with diabetes who
have good control of glycemia, especially when other effective treatments, such as statins
and aspirin, are used frequently.
There are several limitations of the ACCORD BP trial. First, the trial had an open-label
design, a design that was not likely to have affected blood-pressure goals or measurement or
the blinded ascertainment of the outcomes but may have affected the reporting of adverse
events; second, the rate of cardiovascular events was lower than the expected rate in the
standard-therapy group; and third, patients younger than 40 years of age were not included
in the study and patients older than 79 years of age were not included after the vanguard
phase. In addition, although it was not the intent of this trial to test the blood-pressure goal
of 130 mm Hg that was recommended in the JNC 7 (a recommendation that was made after
the ACCORD trial was initiated), it would be difficult to argue that such a target would be
better than a target of 140 mm Hg, since even a blood-pressure goal of 120 mm Hg did not
confer benefit.
In conclusion, the ACCORD BP trial evaluated the effect of targeting a systolic blood
pressure of 120 mm Hg, as compared with a goal of 140 mm Hg, among patients with type 2
diabetes at high risk for cardiovascular events. The results provide no evidence that the
strategy of intensive blood-pressure control reduces the rate of a composite of major
cardiovascular events in such patients.
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Figure 1. Mean Systolic Blood-Pressure Levels at Each Study Visit
I bars indicate 95% confidence intervals.
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Figure 2. Kaplan-Meier Analyses of Selected Outcomes
Shown are the proportions of patients with events for the primary composite outcome (Panel
A) and for the individual components of the primary outcome (Panels B, C, and D). The
insets show close-up versions of the graphs in each panel.
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Age — yr 62.2±6.9 62.2±6.8 62.2±6.9 0.82
Female sex— no. (%) 2258 (47.7) 1128 (47.8) 1130(47.7) 0.95
Race or ethnic group — no. (%)†
    Non-Hispanic white 2864 (60.5) 1455 (61.6) 1409 (59.4) 0.13
    Black 1142 (24.1) 561 (23.8) 581 (24.5) 0.56
    Hispanic 330 (7.0) 159 (6.7) 171 (7.2) 0.53
Education — no./total no. (%) 0.18
    Less than high school 771/4729(16.3) 404/2359(17.1) 367/2370 (15.5)
    High-school graduate or GED 1271/4729 (26.9) 606/2359 (25.7) 665/2370 (28.1)
    Some college 1530/4729 (32.4) 776/2359 (32.9) 754/2370 (31.8)
    College degree or higher 1157/4729 (24.5) 573/2359 (24.3) 584/2370 (24.6)
Previous cardiovascular event— no. (%) 1593 (33.7) 804 (34.0) 789 (33.3) 0.58
Previous heart failure — no./total no. (%) 203/4683 (4.3) 109/2338 (4.7) 94/2345 (4.0) 0.28
Cigarette-smoking status — no./total no.(%) 0.94
    Current 626/4728 (13.2) 314/2358 (13.3) 312/2370(13.2)
    Former 1981/4728 (41.9) 992/2358 (42.1) 989/2370 (41.7)
    Never 2121/4728 (44.9) 1052/2358 (44.6) 1069/2370 (45.1)
Weight — kg 92.0±18.6 92.1±19.4 91.8±17.7 0.57
Body-mass index 32.1±5.6 32.2±5.7 32.1±5.4 0.58
Blood pressure — mm Hg‡
    All participants
        Systolic 139.2±15.8 139.0±16.1 139.4±15.5 0.47
        Diastolic 76.0±10.4 75.9±10.6 76.0±10.2 0.87
    Participants taking no medication at screening
        Systolic 139.4±14.3 139.8±15.0 139.1±13.7 0.53
        Diastolic 77.5±9.4 77.5±9.5 77.4±9.4 0.86
    Participants taking at least one medication at screening
        Systolic 139.2±16.0 138.9±16.3 139.4±15.8 0.34
        Diastolic 75.7±10.5 75.7±10.7 75.8±10.3 0.87
Duration of diabetes — yr 0.86
    Median 10 9 10
    Interquartile range 5–15 5–15 5–15
Glycated hemoglobin — % 8.3±1.1 8.4±1.1 8.3±1.1 0.08
Fasting plasma glucose — mg/dl 174.7±57.7 176.1±57.7 173.2±57.7 0.09
Cholesterol — mg/dl
    Total 192.8±44.7 194.1±45.1 191.4±44.3 0.04






























    Low-density lipoprotein 110.0±36.7 111.1±37.4 108.8±36.0 0.03
    High-density lipoprotein
        Women 51.3±13.8 51.3±13.4 51.3±14.3 0.99
        Men 41.7±11.8 41.4±11.2 42.0±12.4 0.17
Plasma triglycerides — mg/dl 0.71
    Median 147 147 147
    Interquartile range 98–226 98–227 98–224
Potassium — mg/dl 4.5±0.7 4.5±0.5 4.5±0.8 0.73
Serum creatinine — mg/dl 0.9±0.2 0.9±0.2 0.9±0.2 0.98
Estimated GFR — ml/min/1.73 m2 91.6±28.8 91.6±30.3 91.7±27.1 0.93
Ratio of urinary albumin (mg) to creatinine (g) 0.64
    Median 14.3 14.6 14.0
    Interquartile range 6.9–44.8 7.0–43.7 6.9–45.8
*
Plus-minus values are means +SD. Percentages may not total 100 because of rounding. To convert the values for glucose to millimoles per liter,
multiply by 0.055551. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to
millimoles per liter, multiply by 0.01129. To convert the values for potassium to millimoles per liter, multiply by 0.2558. To convert the values for
creatinine to micromoles per liter, multiply by 88.4. GED denotes general equivalency diploma, and GFR glomerular filtration rate.
†
Race or ethnic group was self-reported, and participants could check multiple categories.
‡
Data were available for 4733 participants in the total cohort, 599 who were taking no medication at screening and 4134 who were taking one or
more medications at screening.





























(N = 2371) P Value
Serious adverse events — no. (%)†
Event attributed to blood-pressure medications 77 (3.3) 30(1.27) <0.001
    Hypotension 17 (0.7) 1 (0.04) <0.001
    Syncope 12 (0.5) 5 (0.21) 0.10
    Bradycardia or arrhythmia 12 (0.5) 3 (0.13) 0.02
    Hyperkalemia 9 (0.4) 1 (0.04) 0.01
    Angioedema 6 (0.3) 4(0.17) 0.55
    Renal failure 5 (0.2) 1 (0.04) 0.12
End-stage renal disease or need for dialysis 59 (2.5) 58 (2.4) 0.93
Symptoms affecting quality of life — no./total no. (%)‡
Hives or swelling 44/501 (8.8) 41/468 (8.8) 1.00
Dizziness when standing 217/501 (44.3) 188/467 (40.3) 0.36
Adverse laboratory measures — no. (%)
Potassium <3.2 mmol/liter 49 (2.1) 27(1.1) 0.01
Potassium >5.9 mmol/liter 73 (3.1) 72 (3.0) 0.93
Elevation in serum creatinine
    >1.5 mg/dl in men 304 (12.9) 199 (8.4) <0.001
    >1.3 mg/dl in women 257 (10.9) 168(7.1) <0.001
Estimated GFR <30 ml/min/1.73 m2 99 (4.2) 52 (2.2) <0.001
Clinical measures∫
Glycated hemoglobin — % 7.6±1.3 7.5±1.2 0.13
Fasting plasma glucose — mg/dl 147.1±56.6 148.1±57.5 0.58
Plasma LDL cholesterol — mg/dl 98.7±40.3 96.8±37.8 0.10
Plasma HDL cholesterol — mg/dl 46.7±14.0 47.8±14.9 0.02
Plasma triglycerides — mg/dl 0.001
    Median 138 131
    Interquartile range 97–210 92–197
Potassium — mg/dl 4.3±0.5 4.4±0.5 0.17
Serum creatinine — mg/dl 1.1±0.4 1.0±0.5 <0.001
Estimated GFR — ml/min/1.73 m2 74.8±25.0 80.6±24.8 <0.001
Ratio of urinary albumin (mg) to creatinine (g) <0.001
    Median 12.6 14.9
    Interquartile range 6.4–1.7 7.0–56.8
Microalbuminuria — no./total no. (%) 656/2174 (30.2) 712/2205 (32.3) 0.13
Macroalbuminuria — no. /total no. (%) 143/2174 (6.6) 192/2205 (8.7) 0.009



























(N = 2371) P Value
Serious adverse events — no. (%)†
Weight — kg 93.3±21.2 92.5±20.2 0.20
*
Plus-minus values are means +SD. To convert the values for glucose to millimoles per liter, multiply by 0.055551. To convert the values for
cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To
convert the values for potassium to millimoles per liter, multiply by 0.2558. To convert the values for creatinine to micromoles per liter, multiply
by 88.4. GFR denotes glomerular filtration rate, HDL high-density lipoprotein, and LDL low-density lipoprotein.
†
Serious adverse events are events that are life-threatening, cause permanent disability, or necessitate hospitalization (see Section 7 in
Supplementary Appendix 1).
‡
Symptoms were assessed at 12, 36, and 48 months after randomization in a random sample of 969 participants who were assessed for health-
related quality of life.
∫
Data are from the last visit at which assessments were made for each participant.






























































































































































































   



















   


























   



























   

























































































































































































































































































N Engl J Med. Author manuscript; available in PMC 2014 August 06.
